Нейрогенный и идиопатический гиперактивный мочевой пузырь: камни преткновения
- Авторы: Коршунова Е.С.1,2,3, Коршунов М.Н.1, Даренков С.П.1
-
Учреждения:
- ФГБУ ДПО ЦГМА
- ФГБУ «НМИЦ радиологии»
- ФГБУ НЦН
- Выпуск: Том 21, № 7 (2019)
- Страницы: 53-57
- Раздел: Статьи
- URL: https://ogarev-online.ru/2075-1753/article/view/96823
- DOI: https://doi.org/10.26442/20751753.2019.7.190384
- ID: 96823
Цитировать
Полный текст
Аннотация
Полный текст
Открыть статью на сайте журналаОб авторах
Екатерина Сергеевна Коршунова
ФГБУ ДПО ЦГМА; ФГБУ «НМИЦ радиологии»; ФГБУ НЦН
Email: e_korshunova@mail.ru
канд. мед. наук, доц. каф. урологии, ст. науч. сотр., нейроуролог
Максим Николаевич Коршунов
ФГБУ ДПО ЦГМА
Email: m_korshunov@bk.ru
канд. мед. наук, доц. каф. урологии
Сергей Петрович Даренков
ФГБУ ДПО ЦГМАд-р мед. наук, проф., зав. каф. урологии
Список литературы
- Stewart W.F, Van Rooyen J.B, Cundiff G.W et al. Prevalence and burden of over-active bladder in the United States. World J Urol 2003; 20: 327-36.
- Lai HH, Shen B, Rawal A, Vetter J. The relationship between depression and overactive bladder/urinary incontinence symptoms in the clinical OAB population. BMC Urol 2016; 16: 60. doi: 10.1186/s12894-016-0179-x
- Haylen B.T, de Ridder D, Freeman R.M et al. An International Urogynecological Association (IUGA) / International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010; 29: 4-20; International Urogynecology J 2010; 21: 5-26. DOI: 10.1007 / s00192-009-0976-9
- Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology 2003; 62 (5): 28-37.
- Irwin D.E, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50 (6): 1306-14.
- Коршунова Е.С. Диагностика и лечение симптомов нижних мочевых путей у больных болезнью Паркинсона в сочетании и без доброкачественной гиперплазии простаты. Автореф. дис. … канд. мед. наук. М., 2006. [Korshunova E.S. Diagnostika i lechenie simptomov nizhnikh mochevykh putei u bol'nykh bolezn'iu Parkinsona v sochetanii i bez dobrokachestvennoi giperplazii prostaty. Avtoref. dis. … kand. med. nauk. Moscow, 2006 (in Russian).]
- Litwiller S.E, Frohman E.M, Zimmern P.E. Multiple sclerosis and the urologist. J Urol 1999; 161 (3): 743-57.
- Cacabelos R, Rodríguez B, Carrera C et al. APOE-related frequency of cognitive and noncognitive symptoms in dementia. Methods Find Exp Clin Pharmacol 1996; 18 (10): 693-706.
- Mansfield K.J, Liu L, Mitchelson F.J et al. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharm 2005; 144: 1089-99.
- Ikeda K, Kobayashi S, Suzuki M et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder ands alivary gland. Naunyn-Schmiedeberg’s Arch Pharmacol 2002; 366: 97-103.
- Isik A.T, Celik T, Bozoglu E, Doruk H. Trospium and cognition in patients with late onset Alzheimer disease. J Nutr Health Aging 2009; 13 (8): 672-6.
- Pietzko A, Dimpfel W, Schwantes U, Topfmeier P. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994; 47: 337-43.
- Callegari E, Malhotra B, Bungay P.J et al. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol 2011; 72 (2): 235-46. doi: 10.1111/j.1365-2125.2011.03961.x
- Rudy D, Cline K, Harris R et al. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU Int. 2006; 97 (3): 540-6.
- Position Statement. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013; 20 (9): 888-902.
- Ковалева Л.А. Гиперактивный мочевой пузырь у женщин, особенности терапии. Лечащий врач. 2016; 3: 34-7. [Kovaleva L.A. Giperaktivnyi mochevoi puzyr' u zhenshchin, osobennosti terapii. Lechashchii vrach. 2016; 3: 34-7 (in Russian).]
- Haylen B.T, de Ridder D, Freeman R.M et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010; 29: 4. DOI: 10.1002 / nau.20798
- Robinson D, Cardozo L, Milsom I et al. Oestrogens and overactive bladder. Neurourol Urodyn 2014; 33 (7): 1086-91. doi: 10.1002/nau.22464
- Thuroff J.W, Abrams P, Andersson K.E et al. EAU guidelines on urinary incontinence. Eur Urol 2011; 59: 387-400.
- Rahn D.D, Ward R.M, Sanses T.V. Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelines. Int Urogynecol J 2014. doi: 10.1007/s00192-014-2554-z
- Ellsworth P, Marschall-Kehrel D, King S et al. Bladder health across the life course. Int J Clin Pract 2013; 67: 397-406. DOI: 10.1111 / ijcp.12127
- Wróbel A. Overactive bladder syndrome pharmacotherapy: future treatment options. Prz Menopauzalny 2015; 14 (4): 211-7. DOI: 10.5114 / pm.2015.56403
- Cardoso L, Lose G, McClish D. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand 2004; 83: 892-7.
- Geoffrion, R, Lovatsis, D, Walter J-E et al. Treatments for Overactive Bladder: Focus on Pharmacotherapy. J Obstet Gynaecol Canada 2012; 34 (11): 1092-101. doi: 10.1016/s1701-2163 (16)35440-8
- Geller EJ, Crane AK, Wells EC et al. Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women. Clin Drug Investig 2012; 32 (10): 697-705. DOI: 10.2165 / 11635010-000000000-00000
- Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 2008; 56 (12): 2203-10. doi: 10.1111/j.1532-5415.2008.02009.x
- Fox C, Richardson K, Maidment I.D et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc 2011; 59 (8): 1477-83. doi: 10.1111/j.1532-5415.2011.03491.x
- Ancelin M.L, Artero S, Portet F et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006; 332 (7539): 455-9.
- Chung A, Noguchi N, Chan L, Tse V. Voiding dysfunction in older men. Curr Opin Urol 2016; 26 (2): 177-83. doi: 10.1097/MOU.0000000000000265
- Athanasopoulols A, Gyftopoulos K, Giannitsas K et al. Combination treatment with an a-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlledstudy. J Urol 2003; 169 (6): 2253-6.
- Kaplan S A, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005; 174 (6): 2273-5.
- Yang Y, Zhao S.F, Li H.Z et al. Efficacy and safety of combined therapy with terazosin and tolterodine for patients with lower urinary tractsymptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J 2007; 120 (5): 370-4.
- Kaplan S.A, Roehrborn CG, RovnerES et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. JAMA 2006; 296 (19): 2319-28.
- http://uroweb.org/guideline
- http://www.auanet.org/guidelines
- Wiedemann A, Neumann G, Neumeister C et al. Efficacy and Tolerability of Add-On Trospium Chloride in Patients with Benign Prostate Syndrome and Overactive Bladder: A Non-Interventional Trial Showing Use of Flexible Dosing. Uro Today Int J 2009; 2. doi: 10.3834/uij.1944-5784.2009.04.02
- MacDiarmid S.A, Ellsworth P.I, Ginsberg D.A et al. Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder. Urology 2011; 77 (1): 24-9. doi: 10.1016/j.urology.2010.07.469
- Kosilov K.V, Loparev S.A, Ivanovskaya M.A, Kosilova LV. Effectiveness of Solifenacin and Trospium for Managing of Severe Symptoms of Overactive Bladder in Patients With Benign Prostatic Hyperplasia. Am J Mens Health 2016; 10 (2): 157-63. doi: 10.1177/1557988315595692
- Guay, D.R.P. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet 2003; 42: 1243-85.
- Ohtake A, Saitoh C, Yuyama H. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull 2007; 30: 54-8.
- Chapple, C.R, Khullar, V, Gabriel, Z. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 543-62.
- De Montellano O, Paul R. Cytochrome P450: structure, mechanism, and biochemistry. 3rd edition. New York: Kluwer Academic/Plenum Publishers, 2005.
- Crewe H.K, Lennard M.S, Tucker G.T. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34: 262-5.
- Yaïch M, Popon M, Médard Y. In-vitro cytochrome P450 dependent metabolism of oxybutynin to N-deethyloxybutynin in humans. Pharmacogenetics 1998; 8 (5): 449-51.
- Коршунова Е.С., Коршунов М.Н. Гиперактивный мочевой пузырь у мультиморбидных больных. Что нужно помнить? Consilium Medicum. 2018; 20 (7): 41-5. doi: 10.26442/2075-1753_2018.7.41-45 @@Korshunova E.S., Korshunov M.N. Hyperactive bladder in multimorbid patients. What should be remembered? Consilium Medicum. 2018; 20 (7): 41-5. doi: 10.26442/2075-1753_2018.7.41-45 (in Russian).]
- Zanger, U.M, Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138: 103-41. DOI: 10.1016 / j.pharmthera.2012.12.007
Дополнительные файлы
